Key Details
Price
$9.66Annual ROE
-107.04%Beta
0.98Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA.
Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Galafold dominates its market segment, and a licensing deal with Teva de-risks future growth, positioning it for a continued revenue increase.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.
FAQ
- What is the ticker symbol for Amicus Therapeutics?
- Does Amicus Therapeutics pay dividends?
- What sector is Amicus Therapeutics in?
- What industry is Amicus Therapeutics in?
- What country is Amicus Therapeutics based in?
- When did Amicus Therapeutics go public?
- Is Amicus Therapeutics in the S&P 500?
- Is Amicus Therapeutics in the NASDAQ 100?
- Is Amicus Therapeutics in the Dow Jones?
- When was Amicus Therapeutics's last earnings report?
- When does Amicus Therapeutics report earnings?
- Should I buy Amicus Therapeutics stock now?